Ischemic stroke is a leading cause of disability worldwide, with profound economic costs. Poststroke motor impairment is the most commonly encountered deficit resulting in significant disability and is the primary driver of stroke-associated healthcare expenditures. Although many patients derive some degree of benefit from physical rehabilitation, a significant proportion continue to suffer from persistent motor impairment. Noninvasive brain stimulation, vagal nerve stimulation, epidural cortical stimulation, and deep brain stimulation (DBS) have all been studied as potential modalities to improve upon the benefits derived from physical therapy alone. These neuromodulatory therapies aim primarily to augment neuroplasticity and drive functional reorganization of the surviving perilesional cortex.

The authors have proposed a novel and emerging therapeutic approach based on cerebellar DBS targeted at the dentate nucleus. Their rationale is based on the extensive reciprocal connectivity between the dentate nucleus and wide swaths of cerebral cortex via the dentatothalamocortical and corticopontocerebellar tracts, as well as the known limitations to motor rehabilitation imposed by crossed cerebellar diaschisis. Preclinical studies in rodent models of ischemic stroke have shown that cerebellar DBS promotes functional recovery in a frequency-dependent manner, with the most substantial benefits of the therapy noted at 30-Hz stimulation. The improvements in motor function are paralleled by increased expression of markers of synaptic plasticity, synaptogenesis, and neurogenesis in the perilesional cortex. Given the findings of preclinical studies, a first-in-human trial, Electrical Stimulation of the Dentate Nucleus Area (EDEN) for Improvement of Upper Extremity Hemiparesis Due to Ischemic Stroke: A Safety and Feasibility Study, commenced in 2016. Although the existing preclinical evidence is promising, the results of this Phase I trial and subsequent clinical trials will be necessary to determine the future applicability of this therapy.

https://thejns.org/doi/abs/10.3171/2018.5.FOCUS18164

**KEYWORDS** stroke; deep brain stimulation; cerebellum; rehabilitation
can be realized is typically limited to the 3–6 months following the stroke, after which residual deficits typically stabilize. As a result, even with the benefits provided by physical rehabilitation, many patients remain significantly impaired and incapable of caring for themselves without assistance. In addition to reducing functional independence, poststroke motor impairments are also associated with increased healthcare expenditures. In the United States, the indirect costs associated with stroke are expected to rise from $25 billion in 2010 to $44 billion in 2030. Direct expenses related to stroke are anticipated to increase more than 3-fold—from $71.6 to $184.1 billion—during the same time period. To reduce the burden of physical disability and alleviate the enormous burden poststroke care places on the healthcare system, more effective therapies are needed to reduce chronic poststroke motor deficits.

Deep brain stimulation (DBS) is a potential therapeutic modality to aid in the restoration of motor function after stroke. Currently, DBS is approved by the FDA for the treatment of essential tremor and Parkinson disease. Humanitarian device exemptions granted by the FDA have enabled the use of DBS in the treatment of dystonia and obsessive-compulsive disorder as well. Furthermore, ongoing investigations into the use of DBS in the treatment of Alzheimer disease, traumatic brain injury, obesity, depression, and anorexia nervosa, among others, seek to expand the indications for this therapy. The utility of DBS stems from the ability to modulate a wide variety of structures, depending on the targeted region for stimulation. With respect to stroke, our group has investigated over the span of 10 years the use of DBS of the dentatothalamocortical (DTC) pathway to augment poststroke motor rehabilitation. The ongoing translational and clinical research supporting the use of neuromodulation-based approaches in stroke will be reviewed here, with a specific emphasis on dentate nucleus (DN) DBS-based treatment.

Neuroplasticity After Stroke

Neuroplasticity is believed to be the primary mechanism by which poststroke motor recovery occurs, with changes at the synaptic, cellular, and network levels contributing to reorganization of the surviving neural tissue and mediating recovery. Changes in the perilesional cortex as well as in homotopic regions of the contralesional hemisphere have been shown to help facilitate motor recovery. At the network level, functional recovery is associated with reorganization of the somatotopy of the primary motor cortex and increases in cortical excitability. Reorganization of perilesional cortex and functional motor improvements are thus thought to be mediated in part by increased neuronal excitability leading to neuroplastic changes. Under scoring the importance of this process, motor representation in the perilesional cortex and the area devoted to forelimb function have been correlated with recovery of function after stroke. Long-term potentiation (LTP) is a key driver of the synaptic changes that facilitate poststroke recovery. The central concept underlying LTP is Hebbian plasticity, which occurs when repetitive activation by one neuron drives metabolic and morphological adaptations in the target neuron that increase the efficiency through which the first neuron activates the second. The postsynaptic N-methyl-D-aspartate (NMDA) glutamate receptor, CaMKII, and PKC have been shown to be important mediators of LTP. Changes are not restricted to existing synapses, however; there is evidence to suggest that recovery is associated with the formation of new synapses, as evidenced by animal models demonstrating increased synaptophysin expression in the perilesional cortex. Synaptogenesis and modulation of synaptic strength through LTP are essential in motor learning and motor recovery following stroke.

Axonal sprouting and, to a lesser extent, neurogenesis may also contribute to functional reorganization and recovery after stroke. Axonal sprouting occurs both in the perilesional area and in regions distant from the infarct. Axonal sprouting is guided by multiple factors, which act to direct and support growth of the axon. Axonal growth is inhibited by NogoA, EphrinA5, and chondroitin sulfate proteoglycans, whereas GDF10, GAP43, and numerous other cell adhesion, axonal guidance, and cytoskeletal molecules enable growth and sprouting. Supplementing these processes, neuronal stem cells, guided by chemokines and growth factors from newly formed vessels, migrate from the subventricular zone to the core of the infarct. Unfortunately, the magnitude of this neurogenic response is quite small, and there is little evidence to suggest that this response contributes significantly to functional recovery in humans.

Non–DBS-Based Neuromodulation Approaches to Enhance Poststroke Motor Recovery

Several neuromodulatory approaches to poststroke motor recovery have been studied extensively. The lessons learned from these studies have greatly informed the development of DBS of the DTC pathway. Transcranial magnetic stimulation of the motor cortex, one of the most widely used noninvasive brain stimulation (NIBS) modalities, has been used as a prognostic tool to determine integrity of descending motor pathways and to map changes in motor cortex representation during rehabilitation. Repetitive transcranial magnetic stimulation is currently under extensive investigation to examine its effects on motor reorganization and recovery after stroke. Although widespread adoption of NIBS remains hampered by modest therapeutic effect sizes to date and limited patient access to the technology, use of NIBS has aided in the development of a strong evidence base in support of more invasive therapies.

Implantable neurostimulation devices circumvent several of the shortcomings of NIBS by allowing direct, long-term stimulation of the nervous system. Preclinical studies of vagal nerve stimulation (VNS) have shown that stimulation produces numerous physiological changes, including changes in neurotrophic signaling, neuroinflammation, and excitotoxicity in addition to modulation of cerebral blood flow. In rodent models of ischemic stroke, VNS paired with physical rehabilitation led to significant

2 Neurosurg Focus Volume 45 • August 2018
improvements in motor function relative to controls receiving rehabilitation alone. These preclinical findings formed the basis for a recent clinical trial in the United Kingdom. In this trial, 9 patients were randomized to VNS plus rehabilitation and 11 were assigned to rehabilitation alone. Although the intention-to-treat analysis did not reveal any significant difference in upper-extremity function as measured via the Fugl-Meyer Assessment upper extremity score, the per-protocol analysis showed some improvements in the VNS-treated group relative to the rehabilitation alone control group (between-group difference, 6.5; 95% CI 0.4–12.6). Additional studies are necessary to clarify the utility of VNS in the treatment of poststroke motor deficits.

Early studies of epidural cortical stimulation (ECS) for poststroke motor rehabilitation were promising, with both rodent and nonhuman primate studies showing significant motor improvements following ECS. Based on preclinical evidence and the results of Phase I and II clinical trials, a pivotal Phase III trial named Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis (EVER-EST) was conducted in which 146 patients participated (91 treatment, 55 control). Unfortunately, no difference was seen in motor recovery between the ECS plus rehabilitation group and the rehabilitation alone group. In a subsequent analysis, patients who responded favorably to ECS were found to have a significantly greater proportion of intact corticospinal tract and were more likely to demonstrate preserved motor-evoked responses to cortical stimulation than nonresponders. Subsequent studies have demonstrated the importance of infarct location, the timing of stimulation relative to the ischemic insult, the preservation of descending motor pathways, and the need to stimulate wide areas of perilesional cortex to produce benefits in motor function.

Deep Brain Stimulation for Stroke Recovery

Elias et al. recently published a comprehensive review of the literature that aimed to assess the potential use of DBS for recovery from poststroke conditions. The primary aim of the majority of the studies that they identified was relief of other stroke sequelae, including pain, dystonia, and spasticity. With regard to poststroke hemiparesis, only 9 studies, including a total of only 20 patients, have reported the effects of DBS on motor recovery, and none of them included motor function as a primary outcome. Overall, the authors found that the posterior limb of the internal capsule was the target most associated with improvement in paresis in poststroke patients. Numerous problems arise in interpreting these data, however—most notably the fact that these studies were designed to treat poststroke pain, not motor deficits.

We were the first group to propose and investigate the use of DBS of the DTC pathway for poststroke rehabilitation in preclinical models and, more recently, in a first-in-human clinical trial. Our approach carries the potential to address many of the pitfalls and shortcomings of previously investigated neuromodulation therapies for stroke rehabilitation. Its primary strength lies in its ability to modulate wide swaths of perilesional cortex by targeting a compact nodal point in a network with dense projections to a variety of cerebral subcortical and cortical regions. The theoretical underpinnings, preclinical evidence, and ongoing clinical studies regarding cerebellar DBS are reviewed here (Fig. 1).

Anatomical and Pathophysiological Rationale

The robust reciprocal connections between the cerebral cortex and the contralateral cerebellar hemisphere through the cerebropontocerebellar (CPC) and DTC fibers demonstrate the strong interdependence of these structures (Fig. 2). Following a large cortical insult, such as an ischemic stroke, decreased afferent input to the cerebellum secondary to disruption of the CPC tract leads to decreased cerebellar metabolism, blood flow, and activity. This deafferentation and reduced activity of the cerebellum then results in decreased excitatory output from the cerebellum to the affected cortex via the reciprocal DTC pathway. This phenomenon, called crossed cerebellar diaschisis (CCD), is a critical component of the rationale underlying the selection of the DTC tract at the DN as a target to enhance poststroke motor recovery. The incidence of CCD following stroke is variable, with reports
ranging from 16% to greater than 50% in PET and SPECT imaging studies.\textsuperscript{38,58,66} Evidence suggests that CCD is associated with increased stroke severity, and the finding of CCD in the early subacute phase following stroke correlates with worse motor outcomes and decreased cortical excitability.\textsuperscript{28,31,56,58}

The DN, situated adjacent to the fourth ventricle, is the largest of the deep cerebellar nuclei (Fig. 3).\textsuperscript{2} The nucleus is divided into a dorsal motor domain that projects primarily to motor and premotor cortex, and a ventral nonmotor domain that projects to prefrontal and parietal cortex.\textsuperscript{17} The DN receives input from the lateral cerebellar hemisphere as well as the CPC tract by way of various pontine nuclei. Its primary output is the DTC tract, which exits the cerebellum via the ipsilateral superior cerebellar peduncle and decussates in the midbrain before synapsing in the contralateral thalamus via several nuclei, including the ventral lateral pars caudalis, ventral posterior lateral pars oralis, and medial dorsal.\textsuperscript{61} From the thalamus, the DTC tract then projects to several cortical regions, including the premotor, primary motor, and parietal cortices.\textsuperscript{17,18} Given the functional relevance of the reciprocal connectivity between the cerebellum and cerebral cortex illustrated by CCD, and the widespread disynaptic excitatory projections of the DN to the cerebral cortex, cerebellar DBS holds the potential to influence large perilesional cortical areas, with the hypothesized effect of promoting functional reorganization and, in turn, motor recovery.

Preclinical Evidence

The first proof-of-principle study investigating this hypothesis was published by our group in 2009.\textsuperscript{42} In this study, rats were pretrained on the Montoya staircase task before stroke induction, which was conducted using the 3-vessel occlusion approach. Animals were then treated with sham, 10-Hz, 20-Hz, or 50-Hz stimulation of the contralesional lateral cerebellar nucleus (LCN), the rodent analog to the human DN. Relative to the sham-stimulated animals, those receiving chronic 20-Hz stimulation demonstrated significant improvements in motor function as indexed by performance on the Montoya staircase task.

Given the frequency-dependent nature of the improvements seen in the first study and the understanding that increased cortical excitability underlies neuroplastic changes in the cortex, a subsequent study was performed in which concurrent LCN DBS and intracortical microstimulation of the contralesional primary motor cortex were performed in naïve rats.\textsuperscript{3} LCN DBS was again delivered over a range of frequencies, including 20 Hz, 30 Hz, 40 Hz, 50 Hz, or 100 Hz, and the amplitude of the intracortical microstimulation–induced motor evoked potential (MEP) measured across the hindlimb was used to index cortical excitability. The results showed that 30-Hz stimulation resulted in the most sustained facilitation of MEPs, whereas 100-Hz stimulation actually reduced excitability over time. A later study confirmed that although MEPs were less robust in poststroke animals relative to naïve controls, LCN DBS consistently produced frequency-specific modulation of cortical excitability.\textsuperscript{50}

After demonstrating that LCN DBS can promote motor recovery and determining optimal stimulation parameters, studies into the mechanistic underpinnings of the therapy
were undertaken. Immunohistochemical analysis of the perilesional cortex found that the motor benefits of LCN DBS, measured via the pasta matrix task (Fig. 1), were accompanied by increased expression of synaptophysin, a marker of synaptogenesis. Building on this finding, we investigated the effects of chronic 30-Hz stimulation, a burst stimulation pattern, and sham stimulation on motor recovery, perilesional expression of markers of LTP, and reorganization of the motor cortex. In line with previous studies, the efficacy of LCN DBS on motor recovery was once again shown on the pasta matrix task. Western blot analysis of perilesional tissue also demonstrated increased expression of several markers of LTP in stimulated animals—specifically synaptophysin, the NMDA receptor, PSD95, and CamKII. Paralleling this increased expression of markers of neuroplasticity, a 2-fold increase in synaptic density in the perilesional cortex of treated animals was seen via 3D electron microscopy. Finally, intracortical microstimulation of the primary motor cortex showed that stroke induced a significant reduction in the amount of cortex devoted to the forelimb relative to naïve controls. Treatment with LCN DBS resulted in significant expansion of the poststroke forelimb representation relative to sham-stimulated animals. In addition to inducing synaptogenesis and LTP, LCN DBS may also promote neurogenesis in rodent models of stroke. Chan et al. showed that following stroke, LCN DBS–treated animals showed an increased number of cells coexpressing BRDU, a marker of cell proliferation, and several neurogenic markers, indicating the presence of neurogenesis. Interestingly, the neurogenic effect of LCN DBS appeared to be selective for excitatory, glutamatergic neurons relative to inhibitory GABAergic neurons. Combined, the findings of these studies have provided evidence in support of the ability of LCN DBS to promote motor recovery, neuroplasticity, and functional reorganization of the motor cortex.

Ongoing Research and Future Directions

Clinical Studies

Given the preclinical evidence in support of DBS of the DTC pathway, an investigational device exemption (IDE # G150237) was granted to conduct a Phase I trial of DBS of the DN area. Supported by funding from the BRAIN Initiative, a first-in-human trial, Electrical Stimulation of the Dentate Nucleus Area (EDEN) for Improvement of Upper Extremity Hemiparesis Due to Ischemic Stroke: A Safety and Feasibility Study (NCT02835443; see ClinicalTrials.gov), began enrolling patients in 2016. The EDEN study is enrolling patients between the ages of 25 and 75 years who have experienced a single ischemic stroke within the previous 12–36 months and are still experiencing moderate to severe unilateral upper-extremity paresis. In addition to the primary intervention of physical rehabilitation combined with DN stimulation, patients undergo a battery of tests with the goal of collecting data to hone future studies. This includes structural MR imaging, metabolic imaging to detect changes in the cerebellum and cerebral cortex, local field potential recordings from the DN during a lead externalization period, characterization of cortical excitability over time, and changes in perilesional cortical maps. Ancillary data from this study will aid in refining patient selection, DBS targeting, and optimal stimulation parameters to facilitate recovery and minimize side effects. Pending the results of the ongoing Phase I trial, future randomized controlled trials will be necessary to evaluate the ultimate utility of DTC DBS in promoting poststroke motor recovery and reducing disability.

Preclinical Studies

Continued preclinical investigations into LCN DBS are underway. One area of interest is the development of a closed-loop stimulation paradigm. Given the likelihood that the effects of stimulation on neural networks depend at least in part on brain state relative to motor or nonmotor tasks, we anticipate that a closed-loop system designed to deliver stimulation at critical periods of motor activity, or preceding or following motor activity, may provide greater benefit in motor recovery or minimize adverse effects of stimulation relative to continuous chronic stimulation. To this end, our group has recently shown increased beta-
band activity in the LCN prior to the initiation of unsuccessful reaching motions compared to successful attempts, a finding that may allow for the design and development of local field potential–informed closed-loop stimulation triggering. Ongoing work in our laboratory is aimed at developing such a closed-loop system based on real-time detection of animal behavior.

Given the promising findings of DBS in postischemia rehabilitation, we are now extending our research to traumatic brain injury. We aim to evaluate if DBS can promote recovery of motor function after injury as well as other domains of neurological function such as learning and cognition. This work has also enabled the study of the effects of LCN DBS on postinjury apoptosis and neuroinflammation, which may provide additional mechanistic data relevant to the use of cerebellar DBS in disease models.

Optogenetic approaches to target neural circuits involved in stroke recovery are also advancing and can help inform some of the mechanisms underlying the effects of stimulation. Selective optogenetic stimulation of the contralesional LCN neurons at 10 Hz in Thy1-ChR2-YFP transgenic mice has now reproduced the poststroke motor rehabilitative effects first demonstrated with DBS.

Conclusions

Preclinical evidence from rodent models of stroke demonstrate that LCN DBS promotes motor recovery that is paralleled by increased expression of markers of synaptic plasticity, synaptogenesis, neurogenesis, and reorganization of the perilesional motor cortex. Continued laboratory investigations and the ongoing Phase I EDEN trial will help determine the future direction of this promising therapy.

References


Disclosures
Drs. Machado and Baker have distribution rights related to intellectual property in Enspire DBS, Cardionomics, and ATI. Dr. Machado is a consultant to St. Jude Medical, and he receives clinical or research support for the study described (includes equipment or material) from both St. Jude Medical and the NIH. He also is on the scientific advisory board for Enspire and Medtronic.

Author Contributions
Conception and design: all authors. Drafting the article: Wathen, Frizon, Maiti. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Machado. Study supervision: Machado, Baker.

Correspondence
Andre G. Machado: Cleveland Clinic, Cleveland, OH. machada@ccf.org.